meropenem/piperacillin/tazobactam (VIO-001) / Viosera Therap - LARVOL DELTA

Pharmacokinetics, Tissue Distribution, and Efficacy of VIO-001 (Meropenem/Piperacillin/Tazobactam) for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia in Immunocompetent Rabbits with Chronic Indwelling Vascular Catheters. (PubMed, Antimicrob Agents Chemother) - "Study groups in efficacy experiments consisted of M/P/T combination of 100/150/100 (MPT100), 200/300/200 (MPT200), 400/600/400 (MPT400) mg/kg, vancomycin (VAN) at 15 mg/kg, and untreated controls (UC). In summary, VIO-001 demonstrated a favorable PK/PD profile and activity against SISCV MRSA infection, bacteremia, and disseminated infection. This rabbit model provides a new system for understanding new antimicrobial agents against MRSA SISVC-related infection and these data provide a basis for future clinical investigation."

Clinical • Journal • PK/PD data • Preclinical • Infectious Disease